Teva Pharmaceutical’s dreams of a first-in-class autoimmune blockbuster are being kept alive after the Israeli outfit’s anti-interleukin-15 antibody scored a midstage win in celiac disease.
Teva Pharmaceutical’s dreams of a first-in-class autoimmune blockbuster are being kept alive after the Israeli outfit’s anti-interleukin-15 antibody scored a midstage win in celiac disease.